Health: pharmaceuticals; reports on certain costs and other information associated with prescription drugs; require manufacturers of prescription drugs to file with the department. Creates new act.
Key claim: Michigan HB5941 would require prescription-drug manufacturers to file reports on certain costs and other drug-related information with the state department.
Abstract
(HB5941 · 103rd Legislature) Health: pharmaceuticals; reports on certain costs and other information associated with prescription drugs; require manufacturers of prescription drugs to file with the department. Creates new act. Sponsor: Rep. Karl Bohnak ® In committee: H Health Policy Latest action (2026-05-13): Bill Electronically Reproduced 05/12/2026
Why this matters
Drug-price transparency is a recurring policy lever in Michigan’s health-benefits landscape, sitting alongside insulin pricing reports, copay caps, and MCPA-based pricing enforcement. A general manufacturer cost-reporting duty would give the state a standing data stream on drug pricing rather than relying on episodic or product-specific disclosures, potentially informing future coverage and affordability policy for Medicaid and commercial payers.